Fulcrum Therapeutics CFO Esther Rajavelu resigns effective April 21, 2023

Fulcrum Therapeutics, Inc.

CFO Esther Rajavelu resigns effective April 21, 2023 to pursue another opportunity.
Company will conduct an executive search for a new chief financial officer.
Rajavelu enters consulting agreement for up to 3 months; receives $52,780/month plus $6,000 initiation fee.
Vested stock option exercise period extended to 12 months after consulting services end.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Esther Rajavelu

Chief Financial Officer

FULC · Fulcrum Therapeutics, Inc.

Effective: 2023-04-21
Filed: April 5, 2023, 7:59 PM ET

On March 31, 2023, Esther Rajavelu notified Fulcrum Therapeutics, Inc., or Fulcrum, of her intent to resign as chief financial officer and treasurer (and as principal financial officer), effective April 21, 2023, to pursue another opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Esther Rajavelu resigned as Chief Financial Officer at Fulcrum Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On March 31, 2023, Esther Rajavelu notified Fulcrum Therapeutics, Inc., or Fulcrum, of her intent to resign as chief financial officer and treasurer (and as principal financial officer), effective April 21, 2023, to pursue another opportunity.

View on SEC.gov

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-091620

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.